NasdaqCM - Nasdaq Real Time Price USD

Inovio Pharmaceuticals, Inc. (INO)

Compare
2.3200 -1.4400 (-38.30%)
At close: December 13 at 4:00:02 PM EST
2.4400 +0.12 (+5.17%)
After hours: 7:59:40 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
203.4130
832.0100
10,262.2680
1,774.7580
7,411.2200
Operating Expense
119,626.5140
134,258.6670
277,835.7880
302,992.6770
131,493.2640
Operating Income
-119,423.1010
-133,426.6570
-267,573.5200
-301,217.9190
-124,082.0440
Net Non Operating Interest Income Expense
5,273.3890
6,910.5010
3,528.0780
1,426.6330
-5,390.6040
Other Income Expense
1,273.6270
-8,601.1960
-13,607.4100
-3,433.0370
-33,417.6560
Pretax Income
-112,876.0850
-135,117.3520
-277,652.8520
-303,224.3230
-162,890.3040
Earnings from Equity Interest Net of Tax
--
--
-2,165.2130
-434.3870
-4,584.6100
Net Income Common Stockholders
-112,876.0850
-135,117.3520
-279,818.0650
-303,658.7100
-166,411.1570
Diluted NI Available to Com Stockholders
-112,876.0850
-135,117.3520
-279,818.0650
-303,658.7100
-166,411.1570
Basic EPS
-4.43
-6.09
-14.04
-17.45
-12.84
Diluted EPS
-4.43
-6.09
-14.04
-17.45
-12.84
Basic Average Shares
25,346.2690
22,173.6620
19,885.1820
17,402.4830
12,927.2380
Diluted Average Shares
25,346.2690
22,173.6620
19,885.1820
17,402.4830
12,927.2380
Total Operating Income as Reported
-119,423.1010
-143,940.0280
-267,573.5200
-301,217.9190
-124,082.0440
Total Expenses
119,626.5140
134,258.6670
277,835.7880
302,992.6770
131,493.2640
Net Income from Continuing & Discontinued Operation
-112,876.0850
-135,117.3520
-279,818.0650
-303,658.7100
-166,411.1570
Normalized Income
-116,615.7600
-130,454.6070
-271,971.8930
-300,435.8720
-97,141.7390
Interest Income
5,733.5470
8,133.2900
4,782.0300
3,363.0800
3,311.8460
Interest Expense
460.1580
1,222.7890
1,253.9520
1,936.4470
8,702.4500
Net Interest Income
5,273.3890
6,910.5010
3,528.0780
1,426.6330
-5,390.6040
EBIT
-112,415.9270
-133,894.5630
-276,398.9000
-301,287.8760
-154,187.8540
EBITDA
-109,886.4870
-130,391.0250
-270,902.8740
-296,557.0950
-149,560.0640
Reconciled Depreciation
2,529.4400
3,503.5380
5,496.0260
4,730.7810
4,627.7900
Net Income from Continuing Operation Net Minority Interest
-112,876.0850
-135,117.3520
-279,818.0650
-303,658.7100
-166,411.1570
Total Unusual Items Excluding Goodwill
3,739.6750
-4,662.7450
-7,846.1720
-3,222.8380
-69,269.4180
Total Unusual Items
3,739.6750
-4,662.7450
-7,846.1720
-3,222.8380
-69,269.4180
Normalized EBITDA
-113,626.1620
-125,728.2800
-263,056.7020
-293,334.2570
-80,290.6460
12/31/2020 - 12/8/1998

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

VXRT Vaxart, Inc.
0.5920
-0.75%
 
NVAX Novavax, Inc.
9.11
+1.00%
 
IBIO iBio, Inc.
2.3100
-7.97%
 
SRNE Sorrento Therapeutics, Inc.
0.0015
+25.00%
 
OCGN Ocugen, Inc.
0.8574
+0.59%
 
VIR Vir Biotechnology, Inc.
7.45
+0.27%
 
BNTX BioNTech SE
120.38
-0.26%
 
IBRX ImmunityBio, Inc.
2.8700
-5.59%
 
TNXP Tonix Pharmaceuticals Holding Corp.
0.2405
+5.07%
 
MRNA Moderna, Inc.
41.83
-2.31%